Antiadipogenic effects of the mineralocorticoid receptor antagonist drospirenone: Potential implications for the treatment of metabolic syndrome

Endocrinology

Volumn 152, Issue 1, 2011, Pages 113-125

  Caprio, Massimiliano ^a   Antelmi, Antonella ^a   Chetrite, Gérard ^b,c,d   Muscat, Adeline ^b,c   Mammi, Caterina ^a   Marzolla, Vincenzo ^e,f   Fabbri, Andrea ^e   Zennaro, Maria Christina ^g,h,i   Fève, Bruno ^b,c,d  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b U693   (Italy)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d BICÊTRE HOSPITAL   (France)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

^f San Raffaele Sulmona ^*  (Italy)

^g PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^h UNIVERSITÉ PARIS DESCARTES   (France)

ⁱ HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MARKER; DROSPIRENONE; MINERALOCORTICOID RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADIPOGENESIS; ADIPOSE TISSUE; ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG RESPONSE; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; LIPOLYSIS; METABOLIC SYNDROME X; MOUSE; NONHUMAN; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROADIPOCYTE; SUBCUTANEOUS FAT;

ADIPOCYTES; ALDOSTERONE ANTAGONISTS; ANDROSTENES; ANIMALS; CELL DIFFERENTIATION; CELLS, CULTURED; HUMANS; LIPID METABOLISM; METABOLIC SYNDROME X; MICE; RECEPTORS, MINERALOCORTICOID;

EID: 78650805849     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2010-0674     Document Type: Article

References (42)

1. Zennaro MC, Caprio M, Feve B 2009 Mineralocorticoid receptors in the metabolic syndrome. Trends Endocrinol Metab 20:444-451
2. Caprio M, Feve B, Claes A, Viengchareun S, Lombes M, Zennaro MC 2007 Pivotal role of the mineralocorticoid receptor in cortico-steroid-induced adipogenesis. FASEB J 21:2185-2194
3. Guo C, Ricchiuti V, Lian BQ, Yao TM, Coutinho P, Romero JR, Li J, Williams GH, Adler GK 2008 Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflam-matory adipokines. Circulation 117:2253-2261
4. Hirata A, Maeda N, Hiuge A, Hibuse T, Fujita K, Okada T, Kihara S, Funahashi T, Shimomura I 2009 Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovasc Res 84:164-172
5. Steger DJ, Grant GR, Schupp M, Tomaru T, Lefterova MI, Schug J, Manduchi E, Stoeckert Jr CJ, Lazar MA 2010 Propagation of adi-pogenic signals through an epigenomic transition state. Genes Dev 24:1035-1044
6. Tomlinson JJ, Boudreau A, Wu D, Abdou SH, Carrigan A, Gagnon A, Mears AJ, Sorisky A, Atlas E, Hache R J 2010 Insulin sensitization of human preadipocytes through glucocorticoid hormone induction of forkhead transcription factors. Mol Endocrinol 24:104-113
7. Hoppmann J, Perwitz N, Meier B, Fasshauer M, Hadaschik D, Lehnert H, Klein J 2010 The balance between gluco-and mineralo-corticoid action critically determines inflammatory adipocyte responses. J Endocrinol 204:153-164
8. Palacios S, Foidart JM, Genazzani AR 2006 Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism. Maturitas 55:297-307
9. Krattenmacher R 2000 Drospirenone: pharmacology and pharma-cokinetics of a unique progestogen. Contraception 62:29-38
10. Elger W, Beier S, Pollow K, Garfield R, Shi SQ, Hillisch A 2003 Conception and pharmacodynamic profile of drospirenone. Steroids 68:891-905
11. Fuhrmann U, Krattenmacher R, Slater E P, Fritzemeier K H 1996 The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 54:243-251
12. Muhn P, Fuhrmann U, Fritzemeier KH, Krattenmacher R, Schillinger E 1995 Drospirenone: a novel progestogen with anti-mineralocorticoid and antiandrogenic activity. Ann NY Acad Sci 761:311-335
13. White WB, Pitt B, Preston RA, Hanes V 2005 Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension. Circulation 112:1979-1984
14. White WB, Hanes V, Chauhan V, Pitt B 2006 Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in post-menopausal women with hypertension. Hypertension 48:246-253
15. Preston R A, Norris P M, Alonso A B, Ni P, Hanes V, Karara A H 2007 Randomized, placebo-controlled trialofthe effects ofdrospirenone-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women receiving hydrochlorothiazide. Menopause 14:408-414
16. Oelkers W, Foidart JM, Dombrovicz N, Welter A, Heithecker R 1995 Effects of a new oral contraceptive containing an antiminer-alocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 80:1816-1821
17. Archer DF, Thorneycroft IH, Foegh M, Hanes V, Glant MD, Bitterman P, Kempson RL 2005 Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multi-center trial. Menopause 12:716-727
18. Foidart JM, Faustmann T 2007 Advances in hormone replacement therapy: weight benefits of drospirenone, a 17alpha-spirolactone-derived progestogen. Gynecol Endocrinol 23:692-699
19. Tanko LB, Christiansen C 2005 Effects of 17beta-oestradiol plus different doses of drospirenone on adipose tissue, adiponectin and atherogenic metabolites in postmenopausal women. J Intern Med 258:544-553
20. Nisoli E, Clementi E, Tonello C, Sciorati C, Briscini L, Carruba MO 1998 Effects of nitric oxide on proliferation and differentiation of rat brown adipocytes in primary cultures. Br J Pharmacol 125:888-894
21. Gregoire FM, Smas CM, Sul HS 1998 Understanding adipocyte differentiation. Physiol Rev 78:783-809
22. Garthwaite SM, McMahon EG 2004 The evolution of aldosterone antagonists. Mol Cell Endocrinol 217:27-31
23. Singh R, Artaza JN, Taylor WE, Braga M, Yuan X, Gonzalez-Cadavid NF, Bhasin S 2006 Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear translocation of androgen receptor complex with beta-catenin and T-cell factor 4 may bypass canonical Wnt signaling to down-regulate adipogenic transcription factors. Endocrinology 147:141-154
24. Fu M, Sun T, Bookout AL, Downes M, Yu RT, Evans RM, Mangelsdorf DJ 2005 A Nuclear Receptor Atlas: 3T3-L1 adipo-genesis. Mol Endocrinol 19:2437-2450
25. Rondinone CM, Rodbard D, Baker ME 1993 Aldosterone stimulated differentiation of mouse 3T3-L1 cells into adipocytes. Endocrinology 132:2421-2426
26. Dieudonne MN, Pecquery R, Boumediene A, Leneveu MC, Giudicelli Y 1998 Androgen receptors in human preadipocytes and adipo-cytes: regional specificities and regulation by sex steroids. Am J Physiol 274:C 1645-C 1652
27. Wannenes F, Caprio M, Gatta L, Fabbri A, Bonini S, Moretti C 2008 Androgen receptor expression during C2C12 skeletal muscle cell line differentiation. Mol Cell Endocrinol 292:11-19
28. Fournier T, Handschuh K, Tsatsaris V, Guibourdenche J, Evain-Brion D 2008 Role of nuclear receptors and their ligands in human trophoblast invasion. J Reprod Immunol 77:161-170
29. Funder JW 1997 Glucocorticoid and mineralocorticoid receptors: biology and clinical relevance. Annu Rev Med 48:231-240
30. Wildman RP, Muntner P, Reynolds K, McGinn AP, Rajpathak S, Wylie-Rosett J, Sowers MR 2008 The obese without cardiometa-bolic risk factor clustering and the normal weight with cardiometa-bolic risk factor clustering: prevalence and correlates of 2 pheno-types among the US population (NHANES 1999-2004). Arch Intern Med 168:1617-1624
31. Berg AH, Scherer PE 2005 Adipose tissue, inflammation, and cardiovascular disease. Circ Res 96:939-949
32. Toth MJ, Tchernof A, Sites CK, Poehlman ET 2000 Menopause-related changes in body fat distribution. Ann NY Acad Sci 904:502-506
33. Collins P, Rosano G, Casey C, Daly C, Gambacciani M, Hadji P, Kaaja R, Mikkola T, Palacios S, Preston R, Simon T, Stevenson J, Stramba-Badiale M 2007 Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologists. Eur Heart J 28:2028-2040 (Pubitemid 47579557)
34. Rees M, Stevenson J 2008 Primary prevention of coronary heart disease in women. Menopause Int 14:40-45
35. Quinkler M, Meyer B, Bumke-Vogt C, Grossmann C, Gruber U, Oelkers W, Diederich S, Bahr V 2002 Agonistic and antagonistic properties of progesterone metabolites at the human mineralocor-ticoid receptor. Eur J Endocrinol 146:789-799
36. Oelkers W H 2005 Drospirenone in combination with estrogens: for contraception and hormone replacement therapy. Climacteric 8(Suppl 3):19-27
37. Arias-Loza PA, Muehlfelder M, Elmore SA, Maronpot R, Hu K, Blode H, Hegele-Hartung C, Fritzemeier KH, Ertl G, Pelzer T 2009 Differential effects of 17beta-estradiol and of synthetic pro-gestins on aldosterone-salt-induced kidney disease. Toxicol Pathol 37:969-982
38. Karara AH, Hanes V, Alonso A, Ni P, Poola N, Silang R, Blode H, Preston R A 2007 Pharmacokinetics and pharmacodynamicsofdro-spirenone-estradiol combination hormone therapy product coad-ministered with hydrochlorothiazide in hypertensive postmeno-pausal women. J Clin Pharmacol 47:1292-1302
39. Pu Q, Neves M F, Virdis A, Touyz R M, Schiffrin E L 2003 Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension 42:49-55
40. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EA, McMahon EG, Delyani JA 2002 Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 283:H 1802-H 1810
41. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT 2002 Al-dosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol 161:1773-1781
42. Caprio M, Newfell BG, la Sala A, Baur W, Fabbri A, Rosano G, Mendelsohn ME, Jaffe IZ 2008 Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ Res 102:1359-1367